Risk adjustment in studies using administrative data

Schizophrenia Bulletin

Volumn 29, Issue 2, 2003, Pages 267-271

  Sernyak, Michael J ^a,b   Rosenheck, Robert ^b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Administrative data; Evaluation; Risk adjustment; Schizophrenia; Treatment

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MULTIPLE REGRESSION; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; SUBSTANCE ABUSE; TREATMENT OUTCOME;

EID: 0141841720     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a007003     Document Type: Article

References (22)

1. Barnes, T.R. A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154:672-676, 1989.
2. Conley, R.R.; Love, R.C.; Kelly, D.L.; and Bartko, J.J. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. American Journal of Psychiatry, 156(6):863-868, 1999.
3. Frankle, W.G.; Shera, D.; Berger-Hershkowitz, H.; Evins, A.E.; Connolly, C.; Goff, D.C.; and Henderson, D.C. Clozapine-associated reduction in arrest rates of psychotic patients with criminal histories. American Journal of Psychiatry, 158:270-274, 2001.
4. Guy, W. Abnormal involuntary movements. In: Guy, W., ed. ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health, Education, and Welfare Publication 76-338. Rockville, MD: National Institute of Mental Health, 1976a.
5. Guy, W. Clinical Global Impression. In: Guy, W., ed. ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health, Education, and Welfare Publication 76-338. Rockville, MD: National Institute of Mental Health, 1976b.
6. Heinrichs, D.; Hanlon, E.; and Carpenter, W. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin, 10(3):388-398, 1984.
7. Iezzoni, L.I., ed. Risk Adjustment for Measuring Healthcare Outcomes. Chicago, IL: Health Administration Press, 1997.
8. Kay, S.R.; Fiszbein, A.; and Opler, L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2):261-276, 1987.
9. Millenson, M.L. Demanding Medical Excellence: Doctors and Accountability in the Information Age. Chicago, IL: University of Chicago Press, 1997.
10. Overall, J., and Gorham, D. The Brief Psychiatric Rating Scale. Psychological Reports, 10:799-812, 1962.
11. Rabinowitz, J.; Lichtenberg, P.; Kaplan, Z.; Mark, M.; Nahon, D.; and Davidson, M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. American Journal of Psychiatry, 158(2):266-269, 2001.
12. Rosenbaum, P., and Rubin, D. The central role of the propensity score in observational studies for causal effects. Biometrika, 70:41-55, 1983.
13. Rosenbaum, P., and Rubin, D. Reducing bias in observational studies using subclassification on the propensity score. Journal of the American Statistical Association, 79:516-524, 1984.
14. Rosenheck, R.; Banks, S.; and Pandiani, J. Does closing beds in one public mental health system result in increased use of hospital services in other systems? Mental Health Services Research, 2(4):183-189, 2000a.
15. Rosenheck, R.; Banks, S.; Pandiani, J.; and Hoff, R. Does closing inpatient beds increase the risk of incarceration among VA users of public mental health services? Psychiatric Services, 51(10):1282-1287, 2000b.
16. Rosenheck, R.; Cramer, J.; Xu, W.; Thomas, J.; Henderson, W.; Frisman, L.; Fye, C.; and Charney, D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. New England Journal of Medicine, 337(12):809-815, 1997.
17. Rosenheck, R.; Frisman, L.; and Essock, S. Impact of VA bed closures on use of state mental health services. Journal of Behavioral Health Services and Research, 27(1):98-106, 2000c.
18. Rosenheck, R.; Leslie, D.; and Sernyak, M. From clinical trials to real-world practice: Use of atypical antipsychotic medications nationally in the Department of Veterans Affairs. Medical Care, 39(3):302-308, 2001.
19. Sernyak, M.J.; Desai, R.; Stolar, M.; and Rosenheck, R. Impact of clozapine on completed suicide. American Journal of Psychiatry, 158:931-937, 2001a.
20. Sernyak, M.; Rosenheck, R.; Desai, R.; Stolar, M.; and Ripper, G. Impact of clozapine prescription on inpatient resource utilization. Journal of Nervous and Mental Disease, 189:766-773, 2001b.
21. Simpson, G.M., and Angus, J.W. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, 212(Suppl):11-19, 1970.
22. Spitzer, R., and Endicott, J. The Semi-Structured Clinical Interview for Diagnosis. Washington, DC: American Psychiatric Press, 1990.